Trial Profile

Cytopeutics Umbilical Cord Mesenchymal Stem Cells (Cyto-MSC) for Patients With Grade II -IV Acute Graft-Versus-Host Disease: A Phase I/II Clinical Study

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 16 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Umbilical cord derived mesenchymal stem cells Cytopeutics (Primary)
Indications Graft-versus-host disease
Focus Adverse reactions; Therapeutic Use
Acronyms GVHD Cyto-MSC
Sponsors Cytopeutics

Most Recent Events

01 Jan 2024 Planned End Date changed from 31 Dec 2021 to 25 Jan 2024.
01 Jan 2024 Status changed from recruiting to active, no longer recruiting.
27 Feb 2019 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com